These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 35361131)

  • 1. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.
    Castaldo M; Waliszewska-Prosół M; Koutsokera M; Robotti M; Straburzyński M; Apostolakopoulou L; Capizzi M; Çibuku O; Ambat FDF; Frattale I; Gadzhieva Z; Gallo E; Gryglas-Dworak A; Halili G; Jusupova A; Koperskaya Y; Leheste AR; Manzo ML; Marcinnò A; Marino A; Mikulenka P; Ong BE; Polat B; Popovic Z; Rivera-Mancilla E; Roceanu AM; Rollo E; Romozzi M; Ruscitto C; Scotto di Clemente F; Strauss S; Taranta V; Terhart M; Tychenko I; Vigneri S; Misiak B; Martelletti P; Raggi A;
    J Headache Pain; 2022 Mar; 23(1):41. PubMed ID: 35361131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine.
    Kuan AS; Chen SP; Wang YF; Wang SJ
    Cephalalgia; 2023 Oct; 43(10):3331024231208110. PubMed ID: 37851648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
    Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
    BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.
    Lombardi A; Renisi G; Consonni D; Oggioni M; Bono P; Uceda Renteria S; Piatti A; Pesatori AC; Castaldi S; Muscatello A; Riboldi L; Ceriotti F; Gori A; Bandera A
    BMC Infect Dis; 2022 Jan; 22(1):97. PubMed ID: 35090388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review.
    Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB
    Front Public Health; 2021; 9():778964. PubMed ID: 34888290
    [No Abstract]   [Full Text] [Related]  

  • 9. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis.
    Haas JW; Bender FL; Ballou S; Kelley JM; Wilhelm M; Miller FG; Rief W; Kaptchuk TJ
    JAMA Netw Open; 2022 Jan; 5(1):e2143955. PubMed ID: 35040967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status epilepticus as a complication of SARS-CoV-2 vaccination: Two case reports and systematic review with individual patients' data analysis.
    Dasara M; Dono F; Evangelista G; Quintieri P; Liviello D; Cipollone S; Tomassini V; Sensi SL
    Seizure; 2024 Oct; 121():8-16. PubMed ID: 39038383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
    Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
    JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
    Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis.
    Rahmani K; Shavaleh R; Forouhi M; Disfani HF; Kamandi M; Oskooi RK; Foogerdi M; Soltani M; Rahchamani M; Mohaddespour M; Dianatinasab M
    Front Public Health; 2022; 10():873596. PubMed ID: 36091533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
    Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
    Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.